Secukinumab

Anti-IL-17A human monoclonal antibody

Severe hypersensitivity reactions to the active substance or to any of the excipients

Clinically important, active infection (e.g. active tuberculosis).

Subcutaneous application, maintenance dosing every 4 weeks;

Washout period 11 - 19 weeks

Tildrakizumab

Anti IL-23 humanized IgG1/k monoclonal antibody

Clinically important active infection (e.g. active tuberculosis)

Subcutaneous application, maintenance dosing four times per year

Ustekinumab

Anti-IL-12/23 human monoclonal antibody

Clinically important active infection (e.g. active tuberculosis.

Subcutaneous application, maintenance dosing every 12 weeks;

Washout period 9 - 15 weeks